ICPT

Robbins Geller Rudman & Dowd LLP Files Class Action Suit against Intercept Pharmaceuticals, Inc.

[Business Wire] – Robbins Geller Rudman & Dowd LLP today announced that a class action has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Intercept Pharmaceuticals, Inc. moreView todays social media effects on ICPTView the latest stocks trending across Twitter. Click to view dashboardSee who Intercept is hiring […]

Intercept to Present at Upcoming Healthcare Conferences

[GlobeNewswire] – NEW YORK — Intercept Pharmaceuticals, Inc. (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver … moreView todays social media effects on ICPTView the latest stocks trending across Twitter. Click to view dashboardSee who Intercept is hiring next, click here to view […]

Intercept Expands Its Board of Directors With Appointments of Sanj K. Patel and Glenn Sblendorio

[GlobeNewswire] – NEW YORK — Intercept Pharmaceuticals, Inc. (Intercept or the Company) , a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat … moreView todays social media effects on ICPTView the latest stocks trending across Twitter. Click to view dashboardSee who Intercept is hiring next, click here to view […]

Intercept Pharmaceuticals Announces 2012 Financial Results and Provides Business Update

[at noodls] – Continued Development Progress and a Strong Cash Position Conference Call Scheduled Today at 5:30 p.m. ET NEW YORK, March 18, 2013 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), … moreView todays social media effects on ICPTView the latest stocks trending across Twitter. Click to view dashboardSee who Intercept is hiring next, click here to view […]

Intercept Pharmaceuticals Appoints Daniel Regan as Chief Commercial Officer

[at noodls] – NEW YORK, March 4, 2013 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel … moreView todays social media effects on ICPTView the latest stocks trending across Twitter. Click to view dashboardSee who Intercept is hiring next, click here to view […]

Intercept Pharmaceuticals to Present at the Cowen and Company 33rd Annual Healthcare Conference

[at noodls] – NEW YORK, Feb. 25, 2013 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel … moreView todays social media effects on ICPTView the latest stocks trending across Twitter. Click to view dashboardSee who Intercept is hiring next, click here to view […]

Intercept Pharmaceuticals Announces Initiation of Phase 2 NASH Trial of OCA in Japan

[at noodls] – NEW YORK, Jan. 7, 2013 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel … moreView todays social media effects on ICPTView the latest stocks trending across Twitter. Click to view dashboardSee who Intercept is hiring next, click here to view […]

Intercept Pharmaceuticals Announces Completion of Enrollment in Phase 3 Primary Biliary Cirrhosis POISE Trial

[at noodls] – NEW YORK, Dec. 19, 2012 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel … moreView todays social media effects on ICPTView the latest stocks trending across Twitter. Click to view dashboardSee who Intercept is hiring next, click here to view […]